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Abstract
Background: Both impaired left ventricular (LV) global longitudinal strain (GLS) and increased plasma concentrations of
natriuretic peptides(NP) are associated with a poor outcome in heart failure (HF). Increased levels of NP reflect increased
wall stress of the LV. However, little is known about the relationship between LV GLS and NP. This aim of this study was
to evaluate the relationship between the echocardiographic measure LV GLS and plasma levels of NP.
Methods: We prospectively included 149 patients with verified systolic HF at the baseline visit in an outpatient HF
clinic. LV GLS was assessed by two dimension speckle tracking and plasma concentrations of N-terminal-pro-brain-
natriuretic-peptide (NT-proBNP) and pro-atrial-natriuretic-peptide (proANP) were analysed.
Results: The patients had a median age of 70 years, 28.2 % were females, 26.5 % were in functional class III-IV,
median left ventricular ejection fraction (LVEF) was 33 % and median LV GLS was −11 %. LV GLS was associated with
increased plasma concentrations of NT-proBNP and proANP in multivariate logistic regression (NT-proBNP: Odds
RatioGLS: 7.25, 95 %-CI: 2.48-21.1, P < 0.001 and proANP: Odds RatioGLS: 3.26, 95-%-CI: 1.28-8.30, P = 0.013) and linear
regression (NT-proBNP: βGLS: 1.19, 95 %-CI: 0.62-1.76, P < 0.001 and proANP: βGLS: 0.42, 95-%-CI: 0.11-0.72, P = 0.007)
models after adjustment for traditional confounders (age, gender, body-mass-index, atrial fibrillation, renal function)
and left atrial volume index.
Conclusion: Impaired LV GLS is associated with increased plasma concentrations of NP and our data suggest that left
ventricular myocardial mechanics estimated by LV GLS reflects myocardial wall stress in chronic systolic HF.
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Background
Left ventricular (LV) global longitudinal strain (GLS) is a
novel echocardiographic method to evaluate LV func-
tion. It is more sensitive to LV dysfunction than conven-
tional methods, and strain analysis allows for both
regional and global assessment of the LV [1, 2]. GLS is
reported as a negative value in percentages. A value
closer to cero is a sign of impaired function of the LV.
The normal range has been explored in some studies
and it is reported to be in the region from −15.9 %
to −22.1 %. The variation may be due to age, blood
pressure and technical circumstances [3, 4]. It has been
observed that LV GLS is associated with an increased
risk of mortality and cardiovascular events in patients
with established cardiac disease [5].
Among patients presenting with acute myocardial
infarction, LV GLS is associated with development of
heart failure (HF) and an increased mortality risk [6] as
well as increased plasma concentrations of aminoterminal
pro-brain natriuretic peptide(NT-proBNP) [7]. In chronic
HF it has been shown that LV GLS has additional
prognostic value and it can predict hospitalization for
HF and an increased mortality risk [8–10]. However it re-
mains unknown whether LV GLS reflects e.g., myocardial
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wall stress [11], fibrosis [12] or subclinical ischemia [13] in
chronic HF patients. NT-proBNP is released from the
myocardium when it is exposed to stretch and increased
wall stress [14]. Only few data exist on the relationship
between LV GLS and NT-proBNP in patients with HF,
suggesting association between impaired LV GLS and in-
creased NT-proBNP [15]. Among patients suspected of
HF LV GLS has been reported to be a strong predictor of
NT-proBNP [16]. In asymptomatic patients with echocar-
diographic verified diastolic dysfunction GLS rate showed
the strongest correlation to increased NT-proBNP [17].
In the present study we, therefore, tested the hypoth-
esis that impaired LV GLS is associated with increased
plasma concentrations of NT-proBNP and pro-atrial




Patients were enrolled prospectively at their first visit
when referred to the outpatient HF clinic at North
Zealand Hospital, University of Copenhagen, Denmark.
From January 2011 to November 2012, N = 230 patients
were referred to the HF clinic with LVEF < 45 %. Patients
had to be clinically stable (60 days out of hospital) and
have steady state plasma-creatinine concentration for
60 days (+/−10 μg). A total of N = 149 patients agreed to
participate in an echocardiography study (Cardio-Ren)
[18]. All patients provide written informed consent
according to the Declaration of Helsinki and the study
was approved by the Scientific Ethic Committee (H-1-
2010-074).
At baseline all patients were examined by a physician
and the following information were obtained: medical
history, present symptoms, functional class, medication,
height, weight, non-invasive blood pressure, heart rate,
12-lead electrocardiogram. Venous blood samples were
taken and advanced echocardiography was preformed
according to standard recommendations of the European
Society of Cardiology [19, 20].
Echocardiography
Echocardiography was performed on Vivid 9E (GE
Vingmed Ultrasound, Horten, Norway) and analysed off-
line (Echopac BT 12, 1.0, General Electric, Horten,
Norway). All analysis was performed by a single operator
blinded to plasma concentrations of NT-proBNP and
proANP.
LVEF were determined using the Simpson biplane
model. Two dimensional parasternal view were used to
measure LV dimension and wall thickness. LV mass were
calculated automatically by Echopac software from the
linear dimensions and reported indexed to body surface
area. Maximal left atrial volume were determined from
the biplane area method and indexed to body surface
area. Mitral inflow was evaluated by doppler recordings
and peak velocity of early (E) and atrial filling (A) and
mitral valve deceleration time were measured. Pulsed
wave velocity was measured at both lateral and septal
mitral annulus for myocardial peak early velocity (e’)
and peak systolic velocity (s’). Mean e’ was calculated
from the lateral and septal e’, and used for calculating
E/e’. In case of atrial fibrillation the mean value of e’
from three consecutive cycles was used.
GLS analysis were performed by two-dimensional
speckle tracking in the three standard apical projections
(long axis, four chambers, two chambers). In the echo-
cardiographic examination we aimed for a frame rate
40–80 frames/sec in all images for strain analysis. The
region of interest was set to cover the thickness of the
myocardium. Appropriate tracking were verified visu-
ally and adjusted if necessary. Aortic valve closure were
automated in the analyse and then confirmed visually,
when uncertain it was identified with continuous wave
doppler in the aortic annulus. LV GLS were analysed
for 17 standardised segments, based on these values a
mean value were calculated for each of the three apical
projections and then a total LV GLS were calculated as
the average of the value from the three apical projec-
tions. The Echopac software allows up to one missing
segment in each projection. If two segment values were
missing in one projection we calculated the missing
score as the average of neighbouring segments and then
calculated LV GLS manually. LV GLS analysis could
not be performed when three or more segments were
missing over all or two segments were missing in more
projections. Reproducibility were tested in 25 random
selected patients for both inter- or intra observer vari-
ation. No significant bias were found (intra observa-
tional: mean diff: −0.08 % +/− 1.16 %, P = 0.703; inter
observational: mean diff: 0.19 % +/−1.9 %, P = 0.422).
Plasma analyses
Venous blood were obtained after >8 hours overnight
fast and 15 min rest. At the time of sampling
P-hemoglobin, P-creatinine, P-sodium and P-potassium
were measured. For later analyses plasma were collected
in ethylenediamine tetracetic (EDTA) vial and centrifuged
at 4° (3000 rpm in 10 min) and stored at −80° Celsius.
Plasma concentrations of NT-proBNP were measured on
the Dimension Vista® 1500 from Siemens Medical Solutions
Diagnostics using the LOCI®-technology (Luminescent
Oxygen Channeling Assay) according to the manufacturer
procedure [21]. Total proANP was measured with a
processing-independent radioimmunoassay, which quanti-
tates the total sum of unprocessed and processed N-
terminal proANP fragments [22].
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Statistics
Baseline clinical data, biochemical data (Table 1) and
echocardiographic measures (Table 2) are presented as
percentages for dichotomous variables and interquartile
range (25 %-75 %) for continuous variables. Groups were
compared with Pearson Chi square-test for discrete
variables and t-tests (parametric) and Mann Whitney
U-tests (nonparametric) for continuous variables, as ap-
propriate. Multivariate and univariate regression analyses
were made test the relationship between LV GLS and NT-
proBNP or proANP. Both linear and logistic regression
analyses were tested (Tables 3 and 4). Adjustments were
made for established confounders: gender, age, body mass
index (BMI), atrial fibrillation, left atrial size and plasma
eGFR. Additional univariate regression analyses were used
to crosscheck the relationship between the ability to ob-
tain sufficient image quality for LV GLS analysis and the
co-existing of obesity (BMI >35 kg/m2) or chronic ob-
structive pulmonary disease (no significant relationship
were observed). Statistic results was considered significant
when P < 0.05 (two-sided).
Results
We were able to perform LV GLS analysis in 117 of 149
patients, corresponding to 80 %, and median LV GLS was
−11 %. Ischemic heart disease determined by coronary
angiography was present in 58 % of the patients, and 38 %
of all patients had atrial fibrillation. Baseline characteristic
are presented in Table 1 according to LV GLS below
(more negative) or above (more positive = impaired)
median LV GLS. There were no significant differences
between baseline characteristics in the two groups.
In Table 2 echocardiographic variables are presented.
Patients with a LV GLS above the median had lower
LVEF (P < 0.001), mildly enlarged LV internal dimension
in diastole (P < 0.001) and lower s’ both laterally
(P < 0.001) and medially (P < 0.001). Diastolic function
estimated by mitral valve deceleration time (P = 0.027)
was reduced in patients with LV GLS above the median,
but left atria size and E/e’ were not significantly affected
by LV GLS. Right ventricular systolic function estimated
by TAPSE (P = 0.012) was also reduced in patients with
LV GLS above the median. LV mass index was significantly
Table 1 Baseline characteristics according to values below median (more negative) (n = 65) or above median (more positive)
(n = 52), median GLS (median = −11 %)
Variable Below median GLS Above median GLS p-value
(n = 65) (n = 52)
Age, years 69 (63–76) 71 (67–76) 0.761
Female gender, % 33.8 21.2 0.130
BMIa, kg/m2 26.0 (22.6-30.2) 26.3 (24.5-30.3) 0.214
NYHAb class III-IV, % 23.1 30.8 0.349
Systolic BPc, mmHg 132 (120–147) 120 (110–140) 0.178
Diastolic BPc, mmHg 77 (70–82) 77 (69–84) 0.889
Heart rate, beats/min 64 (56–76) 70 (62–78) 0.188
HFd duration, months 9 (6–12) 12 (6–24) 0.216
Pervious MIe, % 33.8 44.2 0.251
Hypertension, % 67.7 59.6 0.395
Atrial fibrillation, % 24.6 40.4 0.068
ICDf, % 9.5 13.5 0.507
Diabetes, % 20 25 0.518
ApoplexiaCerebri/TCIg, % 12.3 23.1 0.124
ACE-Ih, % 73.8 59.6 0.140
ARBi, % 21.5 32.7 0.174
Beta-blocker, % 87.7 86.5 0.853
MRAj, % 14.1 28.8 0.051
Diuretics, % 69.2 76.9 0.354
Hemoglobine, mmol/l 8.5 (7.0-9.0) 8.8 (8.0-9.3) 0.215
Creatinine, umol/l 80 (68–97) 95 (73–119) 0.254
eGFRk, ml/min/1,73 m2 82 (66–98) 70 (51–95) 0.244
aBody mass index, bNew York Heart Association, cBlood pressure, dHeart failure, eMyocardial infarction, fImplantable cardiac defibrillator, gTransitory cerebral
ischemia, hAngiotensin converting enzyme inhibitor, iAldosterone receptor blocker, jMineralocorticoid receptor antagonist, kEstimated glomerular filtration rate
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higher in patients with a GLS above the median
(P = 0.019).
Plasma concentrations of NT-proBNP and proANP
were significantly higher in patients with LV GLS above
the median (Fig. 1). The overall linear relationship
between LV GLS and log(NT-proBNP) and LV GLS and
log(proANP) are shown in Fig. 2. In multivariate linear
regression models with log(NT-proBNP) and log(proANP)
as response variables and LV GLS as explanatory variable
the associations were significant between LV GLS and
log(NT-proBNP) (β(NT-proBNP) = 1.19 (95 %-CI: 0.62-1.76,
p < 0.001) and LV GLS and log(proANP) (β(proANP) = 0.42,
(95 %-CI: 0.11-0.72, P =0.007). The associations between
impaired LV GLS and log(NT-proBNP), and LV GLS
and log(proANP), respectively, were also significant
in multivariate logistic regression models (Odds Ratio
GLSNT-proBNP 7.25 (95 %-CI: 2.48-21.18, P < 0.001) and
(Odds Ratio GLSproANP 3.26 (95 %-CI: 1.28-8.29, P = 0.013).
Discussion
The main finding of this study is that impaired LV GLS
is associated with increased cardiac wall stress expressed
by elevated plasma concentrations of NT-proBNP and
proANP in chronic systolic HF patients.
Echocardiographic findings and GLS
In the present study of patients with chronic systolic HF
the majority of patients had impaired LV GLS. Patients
with more impaired LV GLS had lower LVEF, and more-
over, LV GLS showed stronger correlation to echocardio-
graphic variables related to systolic function than to
diastolic function. Previous studies have observed same
association between LV GLS and systolic function [5, 8,
10]. LV GLS has also been evaluated in patients with HF
and preserved LVEF and these studies have also identified
LV GLS to be associated with systolic function and not
conventional echocardiographic measures of diastolic dys-
function [23, 24]. These previous findings, including our
result, therefor suggest that LV GLS reflects systolic func-
tion of the LV in both HF with reduced and normal LVEF.
Cardiovascular Biomarkers and GLS
Few studies have examined LV GLS and NP in chronic
systolic HF. In a study of 137 patients with suspected HF
Yoneyama et al. [16] observed that plasma concentrations
of brain-natriuretic-peptide (BNP) were correlated to
functional class, decreased LVEF and an impaired GLS in
patients with both systolic and diastolic dysfunction. This
is supported by Nahum et al. who examined 125 patients
with chronic systolic heart failure and found not only
prognostic value of LV GLS, but also association between
both GLS and NT-proBNP and strain rate and
NT-proBNP [15]. In patients with acute myocardial
infarction Ersbøll et al. observed that impaired LV GLS
was correlated to plasma concentrations of NT-proBNP
[7] and risk of HF during the admission [25]. The previous
and the present studies, therefore, suggest that LV GLS
reflects wall stress in HF patients since plasma concentra-
tion of BNP and NT-proBNP reflect myocardial wall stress
[10]. It should be noted that both LV GLS and natriuretic
peptides may be indirect measures of myocardial wall
stress and future studies should evaluate the relationship
between wall stress based on invasive measures and
LV GLS and plasma concentrations of NP’s before any
Table 2 Echocardiographic variable according to values below or above median GLS, with 75 % interquartile range
Variable Below median GLS Above median GLS p-value
(n = 65) (n = 52)
LVEF biplanea, % 38 (32–42) 27 (20–34) <0.001
LVIDdb, cm 5.00 (4.55-5.55) 5.70 (5.20-6.30) <0.001
Peak GLSc −13 (−15 - -12) −8 (−10 - -6) <0.001
TAPSEd, mm 19.0 (15.0-23.0) 16.0 (14.0-20.8) 0.012
TRmaxe,mmHG 22.52 (8.48-27.25) 16.98 (4.28-26.70) 0.474
s’ medialf, cm/s 5.00 (4.00-6.00) 4.00 (3.00-5.00) <0.001
s’ lateralf, cm/s 6.00 (5.00-7.00) 5.00 (4.00-5.00) 0.001
LAVIg, ml/m2 27.09 (21.18-33.00) 31.57 (23.17-39.10) 0.093
MV deceleration timeh, ms 222 (178–277) 182 (152–223) 0.027
Ei/Aj ratio 0.89 (0.67-1.36) 0.86 (0.62-1.65) 0.937
Ef/e’k 9.68 (7.53-12.20) 10.47 (7.75-15.27) 0.130
LV mass Index, g/m2 123.60 (90.85-153.18) 145 (117.85-194.90) 0.019
aLeft ventricle ejection fraction, bLeft ventricle internal dimension diastole, cPeak left ventricle global longitudinal strain, dTricuspid annular plane systolic
excursion, eMaximal pressure gradient of tricuspid regurgitation, fMyocardial peak systolic velocity, gLeft atrial end systolic volume index, hMitral valve, iMitral
inflow early filling, jMitral inflow atrial filling, kMyocardial early velocity
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firm conclusions can be made. Whether impaired LV GLS
also reflects other aspects than increased wall stress in
chronic systolic HF needs to be investigated in future
biomarker studies including e.g., Galectin 3.
Methodological considerations and perspectives
Some methodological limitations of this study should be
addressed. It is a single center study and consists of a
relatively small cohort. Patients in this study have a
short history of chronic systolic HF, are in stable clinical
condition over past tree month and may not be fully up-
titrated in the recommended HF treatment. Therefore
the results cannot be extrapolated to other groups of
patients or other stages of heart failure.
All patients had performed an echocardiography by a
trained physician. Due to poor acoustic conditions or
atrial fibrillation we were not able to perform LV GLS
analyses in 21.5 % of the patients. Atrial fibrillation is a
challenge when LV GLS is analysed, because of variation
in the electrocardiographic loop duration, but if cycles
of same length are selected, corresponding to a normal
heart rate. LV GLS can be calculated in patients with
atrial fibrillation [26]. It may be speculated that patients
with atrial fibrillation more often have an impaired LV
GLS since atrial fibrillation is associated with increased
plasma concentrations of NP’s [27], but why NP’s are
increased in atrial fibrillation is unknown, and exclusion
of some patients with atrial fibrillation will probably not
result in selection bias. In the present study the preva-
lence of atrial fibrillation did not differ significantly
between the two groups of LV GLS above and below the
Table 4 Univariate and multivariate logistic regression models
Variable Univariate Multivariate
Odds ratio Beta Odds ratio Beta
(95 % CIa) (95 % CI) (95 % CI) (95 % CI)
P-value P-value P-value P-value
GLSb proANP
c 3.37 0.34 3.26 0.42
(1.53-7.40) (0.05-0.16) (1.28-8.30) (0.11-0.72)
0.003 <0.001 0.013 0.007
GLSAge - - 1.05 0.05
(1,00-1.11) (0.03-0.06)
0.075 <0.001








e - - 0.80 −0.05
(0.28-2.29) (−0.38-0.28)
0.671 0.746




f - - 1.00 0.00
(0.99-1.01) (0.00-0.01)
0.960 0.245
aConfidence interval, bGlobal longitudinal strain, cpro-atrial-natriuretic-peptide,
dBody mass index, eAtrial fibrillation, fLeft atrial volume index
Confounders included in the multivariate logistic regression models: Age,
gender, atrial fibrillation, body-mass-index, creatinine, Left atrial volume index
B: Univariate and Multivariate logistic regression models (response:
proANP)(Confounders: age, gender, body mass index, atrial fibrillation,
creatinine, left atrial volume index)B: Univariate and Multivariate logistic
regression models (response: proANP)(Confounders: age, gender, body mass
index, atrial fibrillation, creatinine, left atrial volume index)
Table 3 Univariate and multivariate logistic regression models
Variable Univariate Multivariate
Odds ratio Beta Odds ratio Beta
(95 % CIa) (95 % CI) (95 % CI) (95 % CI)
P-value P-value P-value P-value
GLSb NT-proBNP
c 5.92 0.47 7.25 1.19
(2.59-13.60) (0.15-0.32) (2.48-21.18) (0.62-1.76)
<0.001 <0.001 <0.001 <0.001
GLSAge - - 1.03 0.03
(0.97-1.09) (0.00-0.06)
0.310 0.025








e - - 3.05 0.52
(0.94-0.85) (−0.10-1.14)
0.063 0.099




f - - 1.00 0.00
(0.99-1.02) (−0.01-0.01)
0.647 0.569
aConfidence interval, bGlobal longitudinal strain, cAmino-terminal-pro-brain-
natriuretic-peptide, dBody mass index, eAtrial fibrillation, fLeft atrial
volume index
Confounders included in the multivariate logistic regression models: Age,
gender, atrial fibrillation, body-mass-index, creatinine, LAVI
A: Univariate and Multivariate logistic regression models (response: NT-
proBNP) (confounders: age, gender, body mass index, atrial fibrillation,
creatinine, left atrial volume index)
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median (Table 3). A BMI > 35 kg/m2 and chronic ob-
structive lung disease (prevalent conditions in HF) did
neither influence the echocardiographic image quality
and it was possible to analyse LV GLS in these sub-
groups. Selection bias due poor echocardiographic qual-
ity in certain subgroups seems, therefore, not to be the
case.
Calculation of LV GLS is not yet a standard procedure
in the echocardiographic examination. The challenge of
LV GLS is that it requires good imaging quality of all
three apical standard projections and sinus rhythm is
preferable. LV GLS is only slightly angle dependent [28].
The calculation of LV GLS is automatic after setting the
region of interest and intra- and interobserver variation
is low. Theoretically, if LV GLS is going to be analysed
in clinical practice it may be possible to find patients at
high risk of developing decompensating and worsening
of HF, and an hospitalization might be prevented if a
Fig. 1 a Median NT-proBNP according to GLS above or below median, with 75 % interquartile range. b Median proANP according to global longitudinal
strain above or below median, with 75 % interquartile range. GLS: global longitudinal strain; NT-proBNP: amino-terminal-pro-brain-natriuretic-peptide;
proANP: pro-atrial-natriuretic-peptide
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relevant intervention is applied, but this hypothesis
needs to be validated in a prospective setting.
Conclusion
Impaired LV GLS is associated with increased plasma con-
centrations of NP’s and patients with impaired LV GLS
have more frequent other cardiac abnormalities and dia-
stolic and systolic dysfunction. GLS of the LV is, therefore,
both associated with other structural abnormalities of the
heart and neurohormonal activity. LV GLS is an access-
ible echocardiographic meassure and should be used in
future studies for risk stratification and to identify clin-
ical or scientific scenarios where GLS might be more
useful than NP’s.
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